Literature DB >> 9827938

Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation.

P Hénon1, H Sovalat, M Becker, Y Arkam, M Ojeda-Uribe, J P Raidot, F Husseini, E Wunder, D Bourderont, B Audhuy, D Bouderont.   

Abstract

In order to better define which cell subset contained in graft products might be the most predictive of haemopoietic recovery following autologous blood cell transplantation (ABCT), the relationships between the amounts of reinfused mononuclear cells (MNC), CFU-GM, total CD34+ cells and their CD33 and CD38 subsets. and the successive stages of trilineage engraftment kinetics, were studied in 45 cancer patients, using the Spearman correlation test, a linear regression model and a log-inverse model. No relationship was found between the infused numbers of MNC, CD33+ and CD33- subsets observed and the numbers of days to reach predetermined absolute neutrophil (ANC), platelet and reticulocyte counts. The infused numbers of CFU-GM, CD34+ and CD34+ 38+ cells correlated inconstantly with haemopoietic recovery parameters. The strongest and the most constant correlations were significantly observed between the infused numbers of CD34+ 38- cells and each trilineage engraftment parameter. The log-inverse model determined a threshold dose of 0.05 x 10(6) (= 5 x 10(4)) CD34+ 38- cells/kg, below which the trilineage engraftment kinetics were significantly slower and unpredictable. Post-transplant TBI-conditioning regimens increased the low cell dose-related delay of engraftment kinetics whereas post-transplant administration of haemopoietic growth factors (HGF) seemed to abrogate this delay. This would justify clinical use of HGF only in patients transplanted with CD34+ 38- cell amounts lower than the proposed threshold value. This study suggests that the CD34+ 38- subpopulation, although essentially participating in late complete haemopoietic recovery, is also composed of committed progenitor cells involved in early trilineage engraftment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827938     DOI: 10.1046/j.1365-2141.1998.01066.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.

Authors:  Patricia A Shi; Lorraine K Miller; Luis M Isola
Journal:  Transfusion       Date:  2013-10-16       Impact factor: 3.157

2.  Industrialized GMP Production of CD34+ Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.

Authors:  Philippe Hénon; Marc Kowalczyk; Anne Aries; Christine Vignon; Guillaume Trébuchet; Rachid Lahlil
Journal:  Stem Cell Rev Rep       Date:  2022-04-14       Impact factor: 6.692

3.  A distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile.

Authors:  Alex Q Lee; Hiroaki Konishi; Connie Duong; Sakiko Yoshida; Ryan R Davis; Jonathan E Van Dyke; Masami Ijiri; Bridget McLaughlin; Kyoungmi Kim; Yueju Li; Laurel Beckett; Nitin Nitin; John D McPherson; Clifford G Tepper; Noriko Satake
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

4.  The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells.

Authors:  John M Ninos; Leigh C Jefferies; Christopher R Cogle; William G Kerr
Journal:  J Transl Med       Date:  2006-02-16       Impact factor: 5.531

5.  Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization.

Authors:  Patricia A Shi; Luis M Isola; Janice L Gabrilove; Erin L Moshier; James H Godbold; Lorraine K Miller; Paul S Frenette
Journal:  Stem Cell Res Ther       Date:  2013-03-20       Impact factor: 6.832

Review 6.  Key Success Factors for Regenerative Medicine in Acquired Heart Diseases.

Authors:  Philippe Hénon
Journal:  Stem Cell Rev Rep       Date:  2020-06       Impact factor: 5.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.